# Medpace Holdings, Inc.  Share Price Target ‘$445.66’, now 10.6% Upside Potential

- Link: https://www.directorstalkinterviews.com/medpace-holdings-inc.share-price-target-445.66-now-10.6-upside-potential-2/4121163904
- Published: 2024-07-05T15:48:52+01:00
- Author: Charlotte Edwards

**Medpace Holdings, Inc.** with ticker code (MEDP) now have 8 confirmed analysts
covering the stock with the consensus suggesting a rating of ‘buy’. The range between
the high target price and low target price is between $480.00 and $395.00 with the
average share target price sitting at $445.66. (at the time of writing). Given that
the stocks previous close was at $403.07 and the analysts are correct then there
would likely be a percentage uptick in value of 10.6%. It’s also worth noting that
there is a 50 day moving average of $398.03 and the 200 day MA is $335.53. The company
has a market capitalization of 12.37B. The stock price for the company is currently
$399.09 USD

 The potential market cap would be $13,671,717,644 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 40.77, revenue per share of $63.98
and a 13.89% return on assets.

Medpace Holdings, Inc. is a global provider of clinical research-based drug and 
medical device development services. The Company is focused on providing scientifically
driven outsourced clinical development services to the biotechnology, pharmaceutical
and medical device industries. The Company partners with pharmaceutical, biotechnology,
and medical device companies in the development and execution of clinical trials.
The Company’s drug development services focuses on full-service Phase I-IV clinical
development services and include development plan design, coordinated central laboratory,
project management, regulatory affairs, clinical monitoring, data management and
analysis, pharmacovigilance new drug application submissions, and post-marketing
clinical support. It also provides bio-analytical laboratory services, clinical 
human pharmacology, imaging services, and electrocardiography reading support for
clinical trials. Its operations are based in North America, Europe, and Asia.

Share on: